Breadcrumb Home Studies Studies Search Filter Research Area AllComplications & ComorbiditiesCureTreatmentTuberculosis Study Status AllClosed to AccrualClosed to Follow UpConcludedEnrollingIn DevelopmentParticipants Off Study and Primary Analysis CompletedPending Sort Study Number AscStudy Number Desc Submit Search Showing 14 studies. IMPAACT 2034: Phase 1 Study of the Pharmacokinetics, Safety, and Acceptability of a Single Dose of Pretomanid Added to an Optimized Background Regimen in Children with Rifampicin-Resistant Tuberculosis DAIDS Number 38754 Research Area Tuberculosis Study Status Enrolling IMPAACT 2015: Evaluation of the HIV-1 Reservoir in the Central Nervous System of Perinatally-Infected Youth and Young Adults with Cognitive Impairment DAIDS Number 35123 Research Area Cure and Immunotherapy Study Status Concluded IMPAACT 2008: Phase I/II Multisite, Randomized, Controlled Study of Monoclonal Antibody VRC01 with Combination Antiretroviral Therapy to Promote Clearance of HIV-1-Infected Cells in Infants DAIDS Number 20735 Research Area Cure and Immunotherapy Study Status Participants Off Study and Primary Analysis Completed IMPAACT 2002: Combined Cognitive Behavioral Therapy and a Medication Management Algorithm for Treatment of Depression among Youth Living with HIV in the United States DAIDS Number 12051 Research Area Brain and Mental Health Study Status Participants Off Study and Primary Analysis Completed IMPAACT 2001: A Phase I/II Trial of the Pharmacokinetics, Tolerability, and Safety of Once-Weekly Rifapentine and Isoniazid in HIV-1-infected and HIV-1-uninfected Pregnant and Postpartum Women with Latent Tuberculosis Infection DAIDS Number 12026 Research Area Tuberculosis Study Status Participants Off Study and Primary Analysis Completed P1112: Monoclonal Antibody PK Study DAIDS Number 11903 Research Area Therapeutics Study Status Participants Off Study and Primary Analysis Completed P1110: Safety and PK of RAL in Neonates DAIDS Number 11891 Research Area Treatment Study Status Concluded P1097: Raltegravir PK Study DAIDS Number 11790 Research Area Treatment Study Status Concluded P1096: Phase 1 Study of Live Attenuated Recombinant (cp) 45 Human Parainfluenza Type 3 Vaccine DAIDS Number 11796 Research Area Vaccine Study Status Concluded P1093: PK, Safety, Tolerability and Antiviral Activity of Dolutegravir DAIDS Number 11773 Research Area Therapeutics Study Status Participants Off Study and Primary Analysis Completed Pagination Current page 1 Page 2 Next page Next
IMPAACT 2034: Phase 1 Study of the Pharmacokinetics, Safety, and Acceptability of a Single Dose of Pretomanid Added to an Optimized Background Regimen in Children with Rifampicin-Resistant Tuberculosis DAIDS Number 38754 Research Area Tuberculosis Study Status Enrolling
IMPAACT 2015: Evaluation of the HIV-1 Reservoir in the Central Nervous System of Perinatally-Infected Youth and Young Adults with Cognitive Impairment DAIDS Number 35123 Research Area Cure and Immunotherapy Study Status Concluded
IMPAACT 2008: Phase I/II Multisite, Randomized, Controlled Study of Monoclonal Antibody VRC01 with Combination Antiretroviral Therapy to Promote Clearance of HIV-1-Infected Cells in Infants DAIDS Number 20735 Research Area Cure and Immunotherapy Study Status Participants Off Study and Primary Analysis Completed
IMPAACT 2002: Combined Cognitive Behavioral Therapy and a Medication Management Algorithm for Treatment of Depression among Youth Living with HIV in the United States DAIDS Number 12051 Research Area Brain and Mental Health Study Status Participants Off Study and Primary Analysis Completed
IMPAACT 2001: A Phase I/II Trial of the Pharmacokinetics, Tolerability, and Safety of Once-Weekly Rifapentine and Isoniazid in HIV-1-infected and HIV-1-uninfected Pregnant and Postpartum Women with Latent Tuberculosis Infection DAIDS Number 12026 Research Area Tuberculosis Study Status Participants Off Study and Primary Analysis Completed
P1112: Monoclonal Antibody PK Study DAIDS Number 11903 Research Area Therapeutics Study Status Participants Off Study and Primary Analysis Completed
P1110: Safety and PK of RAL in Neonates DAIDS Number 11891 Research Area Treatment Study Status Concluded
P1096: Phase 1 Study of Live Attenuated Recombinant (cp) 45 Human Parainfluenza Type 3 Vaccine DAIDS Number 11796 Research Area Vaccine Study Status Concluded
P1093: PK, Safety, Tolerability and Antiviral Activity of Dolutegravir DAIDS Number 11773 Research Area Therapeutics Study Status Participants Off Study and Primary Analysis Completed
